As King’s College London (KCL) scientists are once more in the headlines – this time with new ‘plug and play’ drug delivery technology that could offer a
Astellas has added another gene therapy to its pipeline, taking an option on a clinical-stage candidate for a rare genetic form of dementia from UK biotech AviadoBio for around $50 million.